Mostrando 2 resultados de: 2
Evaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials
ArticleAbstract: Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: hPalabras claves:Epidermal growth factor receptor, Head and neck tumors, Humanized monoclonal antibody, nimotuzumabAutores:Aliuska Frías, Carmen Elena Viada, García L., Mabel Álvarez, Macías A.E., Mestre B.F., Osorio M., Pérez Ruiz L., Ramos M., Robaina M., Santiesteban Y., Tania Crombet, Vega A.M.Fuentes:scopusNimotuzumab induces NK cell activation, cytotoxicity, dendritic cell maturation and expansion of EGFR-specific T cells in head and neck cancer patients
ArticleAbstract: Survival benefit and long-term duration of clinical response have been seen using the epidermal growPalabras claves:head and neck cancer, Human epidermal growth factor receptor, monoclonal antibodies, Natural killer cells, T cellsAutores:Barroso M.C., Concha-Benavente F., Cuevas I., Ferris R.L., Frómeta C., García-Bates T.M., González A., Gonzalez Z., Hechavarría E., Lavastida A., Lugiollo M., Mazorra Z., Mestre B.F., Srivastava R.M., Tania Crombet, Valdés A.Fuentes:scopus